Drug intelligence / Profile preview

EXO PERIO

Development stage
Preclinical
Lead developer
Evolutionary Biologics
Modality
Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Intralesional, Topical
01

Overview

EXO PERIO is an allogeneic, acellular exosome-based therapy derived from human umbilical cord Wharton's Jelly mesenchymal stem cells (MSCs). Developed by Evolutionary Biologics, the product contains approximately 30 billion MSC-derived exosomes per 2cc vial. It is designed to promote tissue regeneration, reduce inflammation, and accelerate wound healing, with specific applications in regenerative dentistry (such as bone grafts, periodontal surgeries, root coverage, implant sites, extraction sockets, and sinus lifts) and general tissue repair. The exosomes act as cell-to-cell communication messengers, delivering growth factors, cytokines, and proteins to stimulate the formation of bone, cartilage, dentin, mucosa, and pulp tissue. In December 2024, the FDA issued a warning letter to Evolutionary Biologics, classifying EXO PERIO as an unapproved new drug and unlicensed biological product due to its therapeutic claims.

Brand names
EXO PERIO
Other names
EVO PERIOExo Perio

Beyond the preview

Go deeper on EXO PERIO.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on EXO PERIO.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call